window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 28, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

CONNECTA Therapeutics

  • Central Nervous System,Drug Discovery & Development,Research & Development

    CONNECTA highlights Fragile X data as Phase 2a trial advances

    CONNECTA Therapeutics will present preclinical data supporting its Phase 2a [...]

    July 3, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development

    CONNECTA starts Phase 2a trial of CTH120 for fragile X syndrome

    CONNECTA Therapeutics has started a Phase 2a clinical trial of [...]

    June 10, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CHMP recommends EU approval of Lynavoy for cholestatic pruritus in PBC
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • CHMP recommends approval of NEZGLYAL for rare neurodegenerative disease
    Categories: Central Nervous System, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • Aravind and Alcon launch global retina surgery training centre in India
    Categories: Medical devices, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top